KRAS and acute myeloid leukemia: Additionally, by using targeted next-generation sequencing in patients with FLT3-mutated AML at the time of progression during treatment with FLT3-inhibitor gilteritinib, several mutations that activate RAS/MAPK pathway signaling have been identified, most commonly in NRAS or KRAS.